Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.
OBJECTIVE
To determine the relation between exposure to dideoxyinosine (ddl) and increased CD4 cell counts and suppression of serum p24 antigen in patients infected with the human immunodeficiency virus (HIV).


METHODS
Open-label, phase I study.


METHODS
Two university hospitals. Patients were studied in both inpatient and outpatient settings.


METHODS
Of 36 HIV-infected patients enrolled, 18 had adequate pharmacokinetic information for analysis.


METHODS
Dideoxyinosine was administered intravenously every 12 hours for 2 weeks. Patients were switched to oral administration at twice the intravenous dose. Pharmacokinetic profiles were obtained twice during each period. A 40-fold range of dose was examined.


METHODS
CD4-positive T-lymphocyte counts and serum p24 antigen levels were determined. Plasma area under the ddl concentration-time curve was determined for a single dose and at steady state.


RESULTS
Increases in CD4-positive T-lymphocyte counts were independent of ddl exposure and were proportional to the starting CD4 count. Suppression of circulating p24 antigen was influenced by cumulative exposure to ddl and was statistically significant.


CONCLUSIONS
The CD4-positive T-lymphocyte count increased at low ddl concentrations or exposures; the extent of this increase was directly proportional to the patient's CD4 count at the start of therapy. Suppression of p24 antigen was related to cumulative exposure to ddl. Therapeutic responses can probably be obtained with ddl, while minimizing long-term toxicity, using daily doses of 10 mg/kg body weight, or less.
Drusano
G L
GL
University of Maryland School of Medicine, Baltimore.
Yuen
G J
GJ
Lambert
J S
JS
Seidlin
M
M
Dolin
R
R
Valentine
F T
FT
D000284:Administration, Oral; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects*; D016049:Didanosine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D016655:HIV Core Protein p24 / Q000097:blood / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D006801:Humans; D007262:Infusions, Intravenous; D007958:Leukocyte Count / Q000187:drug effects; D008954:Models, Biological
D016655:HIV Core Protein p24; D016049:Didanosine